<DOC>
	<DOCNO>NCT00740207</DOCNO>
	<brief_summary>The purpose study compare ISOVUE-250 VISIPAQUE 270 motion artifact pain follow intraarterial injection peripheral DSA .</brief_summary>
	<brief_title>Pilot Study Compare ISOVUE®-250 VISIPAQUE™ 270 Motion Artifact Pain Peripheral DSA</brief_title>
	<detailed_description />
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Enroll patient study patient meet follow inclusion criterion : Provides write Informed Consent willing comply protocol requirement ; Is least 18 year age ; Is schedule undergo peripheral DSA diagnosis and/or treatment ( PTA ) PAOD . Exclude patient study patient fulfill inclusion criterion , follow condition observe : Is pregnant lactate female . Exclude possibility pregnancy : test site institution ( serum urine βHCG ) within 24 hour prior start investigational product administration , surgical history ( e.g. , tubal ligation hysterectomy ) , post menopausal minimum 1 year without menses ; Has know allergy one ingredient investigational product ; Has history severe congestive heart failure [ class IV accordance classification New York Heart Association ( NYHA ) ] Was previously enter study receive investigational compound within 30 day admission study ; Has history hypersensitivity iodinate contrast agent ; Has renal impairment ( eGFR &lt; 60 mL/min/1.73 m2 , calculate use Modification Diet Renal Disease [ MDRD ] study equation , ) ; Has medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or postdose followup examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>